Perioperative Management of Empagliflozin, Semaglutide, and Pioglitazone
Empagliflozin must be discontinued 3-4 days before surgery, semaglutide should be held on the morning of surgery, and pioglitazone should be held on the morning of surgery. 1, 2, 3
SGLT2 Inhibitors (Empagliflozin)
Discontinue empagliflozin 3-4 days (72-96 hours) before any surgical procedure to prevent euglycemic diabetic ketoacidosis (DKA), a potentially life-threatening complication. 1, 2, 3
Critical Evidence Supporting Extended Discontinuation:
The American Diabetes Association explicitly recommends stopping SGLT2 inhibitors 3-4 days preoperatively due to euglycemic DKA risk. 1, 2, 3
The 24-hour discontinuation period previously recommended is insufficient. Multiple case reports document euglycemic DKA occurring even when empagliflozin was stopped 48 hours before surgery, demonstrating that pharmacokinetic effects persist beyond 24 hours. 4, 5
Euglycemic DKA is particularly dangerous because blood glucose levels remain normal (or only mildly elevated), making diagnosis challenging and potentially delaying treatment. 4, 5, 6
This complication has been documented after major surgeries including coronary artery bypass grafting and bariatric procedures. 4, 5, 6
Important Caveat:
- Recent large-scale data from emergency surgeries (where patients couldn't withhold SGLT2 inhibitors) showed no increased DKA risk, suggesting the guidance may be overly conservative. 7 However, for elective surgery where you have control over timing, the 3-4 day discontinuation remains the standard of care given the severity of potential complications and multiple documented cases. 1, 2, 3
GLP-1 Receptor Agonists (Semaglutide)
Hold semaglutide on the morning of surgery. 1, 2, 3
Key Considerations:
Current guidelines acknowledge there is limited data on GLP-1 receptor agonists in the perioperative period, particularly regarding delayed gastric emptying effects. 1, 2
Unlike SGLT2 inhibitors, there is no recommendation for extended preoperative discontinuation. 1, 2, 3
Emerging evidence suggests semaglutide may actually reduce 90-day postoperative complications in diabetic patients undergoing surgery, though this requires further prospective validation. 8
The primary concern is delayed gastric emptying increasing aspiration risk, though specific guidance on timing related to this risk is not yet established in major guidelines. 1, 2
Thiazolidinediones (Pioglitazone)
Hold pioglitazone on the morning of surgery along with other oral glucose-lowering agents. 1, 2, 3
Important Context:
Pioglitazone is contraindicated in heart failure patients, which is relevant for perioperative risk stratification. 9
Unlike SGLT2 inhibitors, pioglitazone does not require extended preoperative discontinuation—holding on the morning of surgery is sufficient. 1, 2, 3
Additional Perioperative Diabetes Management
Preoperative Optimization:
Target HbA1c <8% for elective surgeries whenever possible. 1, 2, 3
Metformin should also be held on the day of surgery. 1, 2, 3
Intraoperative Glucose Management:
Target blood glucose 100-180 mg/dL in the perioperative period. 1, 2, 3
Monitor blood glucose every 2-4 hours while NPO and dose with short- or rapid-acting insulin as needed. 1, 2, 3
Insulin Adjustments:
Give 50% of NPH dose or 75-80% of long-acting analog insulin on the morning of surgery. 1, 2, 3
A 25% reduction in basal insulin the evening before surgery achieves better perioperative glucose control with lower hypoglycemia risk compared to usual dosing. 1
Postoperative Resumption
After surgery, restart oral agents when the patient can tolerate oral intake and glucose levels are stable (90-180 mg/dL). 10, 3 For empagliflozin specifically, ensure the patient is metabolically stable, eating normally, and has no ongoing surgical stress before restarting. 4, 5